Assessing the impact of a research funder’s recommendation to consider core outcome sets
Autoři:
Karen L. Hughes aff001; Jamie J. Kirkham aff001; Mike Clarke aff003; Paula R. Williamson aff001
Působiště autorů:
MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom
aff001; Centre for Biostatistics, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
aff002; Centre for Public Health, Institute of Clinical Sciences, Queen’s University Belfast, Royal Victoria Hospital, Belfast, United Kingdom
aff003
Vyšlo v časopise:
PLoS ONE 14(9)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0222418
Souhrn
Background
Core outcome sets (COS) have the potential to reduce waste in research by improving the consistency of outcomes measured in trials of the same health condition. However, this reduction in waste will only be realised through the uptake of COS by clinical trialists. Without uptake, the continued development of COS that are not implemented may add to waste in research. Funders of clinical trials have the potential to have an impact on COS uptake by recommending their use to those applying for funding. The aim of our study was to assess the extent to which applicants followed the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme’s recommendation to search for a COS to include in their clinical trial.
Methods and findings
We examined the outcomes section and detailed project descriptions of all 95 researcher-led primary research applications submitted to the NIHR HTA between January 2012, when the recommendation to search for a COS was included in the guidance for applicants, and December 2015 for evidence that a search for a COS had taken place and rationale for outcome choice in the absence of COS. A survey of applicants was conducted to further explore their use of COS and choice of outcomes with a response rate of 49%. Nine out of 95 applicants (10%) stated in their application that they had searched the COMET (Core Outcome Measures for Effectiveness Trials) Initiative database for a COS and another nine referred to searching for a COS using another method, e.g. a review of the literature. Of the 77 (81%) applicants that did not mention COMET or COS in their application, eight stated in the survey that they had searched the COMET database and ten carried out a search using another method. Some applicants who did not search for a COS gave reasons for their choice of outcomes including taking advice from patients and the public and choosing outcomes used in previous trials.
Conclusion
A funding body can have an impact on COS uptake by encouraging trialists to search for a COS. Funders could take further steps by putting processes in place to prompt applicants to be explicit about searching for COS in their application and notifying the funding board if a search has not taken place. The sources of information used by trialists to make decisions about outcomes in the absence of COS may suggest methods of dissemination for COS.
Klíčová slova:
Research and analysis methods – Database and informatics methods – Medicine and health sciences – Pharmacology – Research design – Clinical medicine – Clinical trials – Drug research and development – Survey research – Surveys – Research assessment – Peer review – Database searching – Science policy – Research funding – Research grants
Zdroje
1. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. Journal of Health Services Research and Policy. 2012;17(1):1–2. doi: 10.1258/jhsrp.2011.011131 22294719
2. Kirkham JJ, Boers M, Tugwell P, Clarke M, Williamson PR. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials. 2013;14(1). doi: 10.1186/1745-6215-14-324 24103529
3. Bautista-Molano W, Navarro-Compán V, Landewé RBM, Boers M, Kirkham JJ, Van Der Heijde D. How well are the ASAS/OMERACT core outcome sets for ankylosing spondylitis implemented in randomized clinical trials? A systematic literature review. Clinical Rheumatology. 2014;33(9):1313–22. doi: 10.1007/s10067-014-2728-6 24970597
4. Araújo F, Cordeiro I, Ramiro S, Falzon L, Branco JC, Buchbinder R. Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. Rheumatology (Oxford, England). 2015;54(6):981–93. doi: 10.1093/rheumatology/keu424 25398382
5. Copsey B, Hopewell S, Becker C, Cameron ID, Lamb SE. Appraising the uptake and use of recommendations for a common outcome data set for clinical trials: A case study in fall injury prevention. Trials. 2016;17(1). doi: 10.1186/s13063-016-1259-7 26965046
6. Mulla SM, Maqbool A, Sivananthan L, Lopes LC, Schandelmaier S, Kamaleldin M, et al. Reporting of IMMPACT-recommended core outcome domains among trials assessing opioids for chronic non-cancer pain. Pain. 2015;156(9):1615–9. doi: 10.1097/j.pain.0000000000000241 26020224
7. Lange T, Rataj E, Kopkow C, Lützner J, Günther KP, Schmitt J. Outcome Assessment in Total Knee Arthroplasty: A Systematic Review and Critical Appraisal. Journal of Arthroplasty. 2017;32(2):653–65.e1. doi: 10.1016/j.arth.2016.09.014 28341034
8. Kirkham JJ, Clarke M, Williamson PR. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. BMJ (Clinical Research Ed). 2017;357:j2262–j.
9. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke M, et al. Choosing important health outcomes for comparative effectiveness research: A systematic review. PLoS ONE. 2014;9(6). doi: 10.1371/journal.pone.0099111 24932522
10. Gorst SL, Gargon E, Clarke M, Blazeby JM, Altman DG, Williamson PR. Choosing important health outcomes for comparative effectiveness research: An updated review and user survey. PLoS ONE. 2016;11(1). doi: 10.1371/journal.pone.0146444 26785121
11. Gorst SL, Gargon E, Clarke M, Smith V, Williamson PR. Choosing important health outcomes for comparative effectiveness research: An updated review and identification of gaps. PLoS ONE. 2016;11(12). 2016-61781-001.
12. Davis K, Gorst SL, Harman N, Gargon E, Williamson PR, Smith V, et al. Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries. PLoS ONE. 2018;13(2). doi: 10.1371/journal.pone.0190695 29438429
13. Gargon E, Gorst SL, Harman NL, Smith V, Matvienko-Sikar K, Williamson PR. Choosing important health outcomes for comparative effectiveness research: 4th annual update to a systematic review of core outcome sets for research. 2018.
14. Clarke M, Williamson P. Core outcome sets and trial registries. Trials. 2015;16(1). doi: 10.1186/s13063-015-0738-6 25971905
15. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney International. 2018;94(6):1053–68. doi: 10.1016/j.kint.2018.08.018 30360959
16. Kirkham JJ, Davis K, Altman DG, Blazeby JM, Clarke M, Tunis S, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. PLoS Medicine. 2017;14(11):1–10. doi: 10.1371/journal.pmed.1002447 Language: English. Entry Date: 20180724. Revision Date: 20180724. Publication Type: journal article. Journal Subset: Biomedical.
17. Young B, Bagley H. Including patients in core outcome set development: issues to consider based on three workshops with around 100 international delegates. Research Involvement and Engagement. 2016;2(25).
18. Alice MB, Lucy B, Philippe R, Bridget Y, Paula RW. Survey indicated that core outcome set development is increasingly including patients, being conducted internationally and using Delphi surveys. Trials, Vol 19, Iss 1, Pp 1–6 (2018). 2018;(1):1. doi: 10.1186/s13063-018-2493-y 29454368
19. Tong A, Crowe S, Gill JS, Harris T, Hemmelgarn BR, Manns B, et al. Clinicians’ and researchers’ perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study. 2018.
20. Nasser M, Clarke M, Chalmers I, Brurberg KG, Nykvist H, Lund H, et al. What are funders doing to minimise waste in research? 2017. p. 1006–7.
Článok vyšiel v časopise
PLOS One
2019 Číslo 9
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania